hMSH2 and hMLH1 Gene Expression Patterns Differ between Lung Adenocarcinoma and Squamous Cell Carcinoma: Correlation with Patient Survival and Response to Adjuvant Chemotherapy Treatment

Abstract

Background

We recently showed that the mRNA levels of mismatch repair (MMR) proteins in non-small cell lung carcinoma (NSCLC) tissue specimens and the phenotypic translation of molecular MMR data refines the biology of the MMR system with consequent diagnostic implications in the clinical assessment of lung cancer patients.

Methods

hMLH1 and hMSH2 mRNA expression was previously evaluated by qPCR for 29 NSCLC patients (13 with squamous cell carcinoma [SQC] and 16 with adenocarcinoma [ADC]) and MMR mRNA levels were converted into clinically distinct phenotypic entities. In this study, we evaluated the correlation of the hMSH2 and hMLH1 mRNA phenotypes with patient survival and their response to adjuvant chemotherapy.

Results

hMSH2 and hMLH1 mRNA phenotypic distribution differed between SQC and ADC. the MMR phenotypes differed also between advanced and early stage SQC. SQC patients with an increased hMSH2 expression had a better outcome than patients with a reduced hMSH2 expression. However, ADC patients with an increased hMSH2 expression had a poor outcome compared to those with low hMSH2 levels. SQC patients with a high hMSH2 expression exhibited a better response to adjuvant chemotherapy, whereas ADC patients with high hMSH2 levels had a poor response. ADC patients with low hMSH2 levels showed good response to adjuvant chemotherapy compared to SQC patients bearing the same phenotypic profile.

Conclusions

Our findings show that MMR mRNA phenotypes may be added to the known biological differences between SQC and ADC. hMLH1 and hMSH2 phenotypes distributed differently according to the NSCLC stage. Distinct MMR mRNA phenotypes in SQC and ADC corresponded to patient response to adjuvant chemotherapy.

Keywords

MMR hMSH2 hMLH1 NSCLC Survival Chemotherapy

References

van der Klift

, Wijnen

, Wagner

. Molecular characterization of the spectrum of genomic deletions in the mismatch repair genes MSH2, MLH1, MSH6, and PMS2 responsible for hereditary non-polyposis colorectal cancer (HNPCC). Genes Chromosomes Cancer 2005; 44: 123–38.

Montazer Haghighi

, Radpour

, Aghajani

, Zali

, Molaei

, Zali

M.R.

. Four novel germline mutations in the MLH1 and PMS2 mismatch repair genes in patients with hereditary non-polyposis colorectal cancer. Int J Colorectal Dis 2009; 24: 885–93.

Fleisher

A.S.

, Esteller

, Wang

. Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability. Cancer Res 1999; 59: 1090–5.

Esteller

, Levine

, Baylin

S.B.

, Ellenson

L.H.

, Herman

J.G.

. MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas. Oncogene 1998; 17: 2413–7.

Sasaki

, Nakamura

. Mutation of the mismatch repair genes for carcinogenesis of sporadic colorectal cancers with RER-positive phenotype. Nippon Rinsho 1996; 54: 1008–13.

Burger

, Den Zinger

, Hammerschmied

C.G.

. Elevated microsatellite alterations at selected tetranucleotides (EMAST) and mismatch repair gene expression in prostate cancer. J Mol Med 2006; 84: 833–41.

Kassem

H.S.

, Varley

J.M.

, Hamam

S.M.

, Margison

G.P.

. Immunohistochemical analysis of expression and allelotype of mismatch repair genes (hMLH1 and hMSH2) in bladder cancer. Br J Cancer 2001; 84: 321–8.

Leach

F.S.

, Hsieh

J.T.

, Molberg

. Expression of the human mismatch repair gene hMSH2: a potential marker for urothelial malignancy. Cancer 2000; 88: 2333–41.

Vageli

, Daniil

, Dahabreh

. Phenotypic mismatch repair hMSH2 and hMLH1 gene expression profiles in primary non-small cell lung carcinomas. Lung Cancer 2009; 64: 282–8.

10.

Wistuba

I.I.

. Genetics of preneoplasia: lessons from lung cancer. Curr Mol Med 2007; 7: 3–14.

11.

Herbst

R.S.

, Heymach

J.V.

, Lippman

S.M.N.

. Lung cancer. N Engl J Med 2008; 359: 1367–80.

12.

Cooper

W.A.

, Kohonen-Corish

M.R.

, Chan

. Prognostic significance of DNA repair proteins MLH1, MSH2 and MGMT expression in non-small-cell lung cancer and precursor lesions. Histopathology 2008; 52: 613–22.

13.

Ollila

, Dermadi Bebek

, Jiricny

, Nyström

. Mechanisms of pathogenicity in human MSH2 missense mutants. Hum Mutat 2008; 29: 1355–63.

14.

Kijas

A.W.

, Studamire

, Alani

. Msh2 separation of function mutations confers defects in the initiation steps of mismatch repair. J Mol Biol 2003; 331: 123–38.

15.

Amin

N.S.

, Nguyen

M.N.

, Oh

, Kolodner

R.D.

. Exo1-dependent mutator mutations: model system for studying functional interactions in mismatch repair. Mol Cell Biol 2001; 21: 5142–55.

16.

Rosell

, Taron

, Massuti

. Predicting response to chemotherapy with early-stage lung cancer. Cancer J 2011; 17: 49–56.

17.

Drotschmann

, Topping

R.P.

, Clodfelter

J.E.

, Salsbury

F.R.

. Mutations in the nucleotide-binding domain of MutS homologs uncouple cell death from cell survival. DNA Repair (Amst) 2004; 3: 729–42.

18.

Salsbury

F.R.

Jr , Clodfelter

J.E.

, Gentry

M.B.

, Hollis

, Scarpinato

K.D.

. The molecular mechanism of DNA damage recognition by MutS homologs and its consequences for cell death response. Nucleic Acids Res 2006; 34: 2173–85.

19.

Cohn

D.E.

, Frankel

W.L.

, Resnick

K.E.

. Improved survival with an intact DNA mismatch repair system in endometrial cancer. Obstet Gynecol 2006; 108: 1208–15.

20.

Lanza

, Gafà

, Santini

, Maestri

, Guerzoni

, Cavazzini

. Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients. J Clin Oncol 2006; 24: 2359–67.